Sensor-Augmented Insulin Pump Therapy: Results of the First Randomized Treat-to-Target Study
- 1 October 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 10 (5), 377-383
- https://doi.org/10.1089/dia.2008.0068
Abstract
Background: The objective of the study was to evaluate the clinical effectiveness and safety of a device that combines an insulin pump with real-time continuous glucose monitoring (CGM), compared to using an insulin pump with standard blood glucose monitoring systems. Methods: This 6-month, randomized, multicenter, treat-to-target study enrolled 146 subjects treated with continuous subcutaneous insulin infusion between the ages of 12 and 72 years with type 1 diabetes and initial A1C levels of ≥7.5%. Subjects were randomized to pump therapy with real-time CGM (sensor group [SG]) or to pump therapy and self-monitoring of blood glucose only (control group [CG]). Clinical effectiveness and safety were evaluated. Results: A1C levels decreased (P < 0.001) from baseline (8.44 ± 0.70%) in both groups (SG, −0.71 ± 0.71%; CG, −0.56 ± 0.072%); however, between-group differences did not achieve significance. SG subjects showed no change in mean hypoglycemia area under the curve (AUC), whereas CG subjects showed an increase (P = 0.001) in hypoglycemia AUC during the blinded periods of the study. The between-group difference in hypoglycemia AUC was significant (P < 0.0002). Greater than 60% sensor utilization was associated with A1C reduction (P = 0.0456). Fourteen severe hypoglycemic events occurred (11 in the SG group and three in the CG group, P = 0.04). Conclusions: A1C reduction was no different between the two groups. Subjects in the CG group had increased hypoglycemia AUC and number of events during blinded CGM use; however, there was no increase in hypoglycemia AUC or number of events in the SG group. Subjects with greater sensor utilization showed a greater improvement in A1C levels.Keywords
This publication has 13 references indexed in Scilit:
- A Pilot Trial in Pediatrics with the Sensor-Augmented Pump: Combining Real-Time Continuous Glucose Monitoring with the Insulin PumpThe Journal of Pediatrics, 2007
- Involvement of Apolipoprotein E in Excess Fat Accumulation and Insulin ResistanceDiabetes, 2007
- Insulin Pump Therapy in Preschool Children with Type 1 Diabetes Mellitus Improves Glycemic Control and Decreases Glucose Excursions and the Risk of HypoglycemiaDiabetes Technology & Therapeutics, 2005
- Continuous Subcutaneous Insulin Infusion and Multiple Dose of Insulin Regimen Display Similar Patterns of Blood Glucose Excursions in Pediatric Type 1 DiabetesDiabetes Technology & Therapeutics, 2005
- Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSIIDiabetes Care, 2005
- A Two-Center Randomized Controlled Feasibility Trial of Insulin Pump Therapy in Young Children With DiabetesDiabetes Care, 2005
- Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin AnalogsDiabetes Care, 2003
- Continuous Subcutaneous Insulin Infusion at 25 YearsDiabetes Care, 2002
- Limitations of Conventional Methods of Self-Monitoring of Blood GlucoseDiabetes Care, 2001
- Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External PumpsDiabetes Care, 1998